The socio-political economy of pharmaceutical mergers: A case study of sanofi and aventis

Technology Analysis and Strategic Management

Volumn 18, Issue 5, 2006, Pages 473-496

  Mittra, James ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORPORATE STRATEGY; CRITICAL ANALYSIS; INNOVATION; MERGER; PHARMACEUTICAL INDUSTRY; POLITICAL ECONOMY;

EID: 34249702694     PISSN: 09537325     EISSN: 14653990     Source Type: Journal    
DOI: 10.1080/09537320601019594     Document Type: Article

References (84)

1. B. A. Lundvall. (ed.), National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning (London, Pinter, 1992)
2. L. Orsenigo, F. Pammolli & M. Riccaboni, Technological change and network dynamics: Lessons from the pharmaceutical industry, Research Policy, 30, 2001, pp. 485-450
3. A. Allansdottir, A. Bonaccorsi, A. Gambardella, M. Mariani, L. Orsenigo, F. Pammolli & M. Riccaboni, Innovation and competitiveness in European biotechnology, Enterprise Papers - no. 7, Enterprise Directorate - General European Commission, 2002;
4. A. Gambardella, L. Orsenigo & F. Pammolli, Global competitiveness in pharmaceuticals: A European perspective, Report Prepared for the Directorate General Enterprise of the European Commission, 2000.
5. V. Walsh, Creating markets for biotechnology, International Journal of Sociology of Agriculture and Food, 10(2), 2002, p. 33.
6. H. Simon, Theories of bounded rationality, in: H. Simon (Ed.), Models of Bounded Rationality: Behavioral Economics and Business Organization Vol. 2 (Cambridge, MA, MIT Press, 1982), pp. 109-133.
7. P. Allen, R. Ramlogan & S. Randles, Complex systems and the merger process, Technology Analysis and Strategic Management, 14(3), 2002, pp. 315-329.
8. Ibid.
9. R. Coombs & S. Metcalfe, Innovation in pharmaceuticals: Perspectives on the co-ordination, combination and creation of capabilities, Technology Analysis & Strategic Management, 14(3), 2002, pp. 261-271
10. P. Danzon, A. Epstein & S. Nicholson, Mergers and acquisitions in the pharmaceutical and biotech industries, NBER Working Paper Series, no. 10536, National Bureau of Economic Research, Cambridge, MA, 2004.
11. Op. cit. ref. 4, p. 321.
12. Op. cit. Coombs & Metcalfe ref. 5, p. 265.
13. Ibid.
14. A. D. James, The strategic management of mergers and acquisitions in the pharmaceutical industry: Developing a resource-based perspective, Technology Analysis & Strategic Management, 14(3), 2002, pp. 299-313.
15. V. Walsh & G. Lodorfos, Technological and organizational innovation in chemicals and related products, Technology Analysis and Strategic Management, 14(3), 2002, pp. 273-298.
16. W. M. Cohen & D. A. Levinthal, Absorptive capacity: A new perspective on learning and innovation, Administrative Science Quarterly, 35, 1990, pp. 128-152.
17. Op. cit. Danzon et al. ref. 5.
18. J. Drews & S. Ryser, Innovation deficit in the pharmaceutical industry, Drug Information Journal, 30, 1996, pp. 97-107.
19. T. E. Cooke, International Mergers and Acquisitions (Blackwell, Oxford, 1988).
20. R. Larsson & S. Finkelstein, Integrating strategic, organizational, and human perspectives on mergers and acquisitions: A case study of synergy realization, Organization Science, 10(1), 1999, pp. 1-26.
21. Ibid., p. 2.
22. L. M. Shelton, Strategic business fits and corporate acquisition: empirical evidence, Strategic Management Journal, 13, 1988, pp. 245-266.
23. Op. cit. ref. 15, p. 15.
24. D. B. Jemison & S. B. Sitkin, Corporate acquisitions: A process perspective, Academy of Management Review, 11(1), 1986, pp. 145-163.
25. M. Lubatkin, R. Calori, P. Very & J. F. Veiga, Managing mergers across borders: A two nation exploration of a nationally bound administrative heritage, Organization Science, 9(6), 1998, pp. 670-684.
26. Ibid., p. 680.
27. S. J. Evenett, The Cross Border Merger and Acquisitions Wave of the Late 1990s, World Trade Institute & CEPR, 14 March 2003.
28. P. Morosini, S. Shane & H. Singh, National cultural distance and cross-border acquisition performance, Journal of International Business Studies, 29(1), 1998, pp. 137-158.
29. K. Chapman & H. Edmond, Mergers/acquisitions and restructuring in the EU chemical industry: Patterns and implications, Regional Studies, 34(8), 2000, pp. 753-767.
30. Ibid.
31. Ibid., p. 758.
32. Ibid., p. 759.
33. M. Arnold & G. Dyer, Sanofi's options with Aventis are complex, Financial Times, 23 January 2004.
34. Op. cit. ref. 15.
35. Op. cit. ref. 28.
36. J. Tait & J. Mittra, Industry challenges, Chemistry & Industry, 6(23), 2004, p. 24;
37. op. cit. Danzon et al. ref. 5;
38. R. Crossley & J. Kordel, Outsourcing peaks and troughs, Chemistry & Industry, 4, 2002, pp. 21-22.
39. Data from Deutsche Bank AG Investment Reports.
40. Op. cit. ref. 15.
41. I. Schein, Organizational Culture and Leadership: A Dynamic View (Jossey-Bass, London, 1985).
42. C. A. O'Reilly, J. Chatman & D. Caldwell, People and organizational culture: A profile comparison approach to assessing person-organization fit, Academy of Management Journal, 34(3), pp. 487-516.
43. S. Teerikangas & P. Very, The culture-performance relationship in M&A: from yes/no to how, British Journal of Management, 17, 2006, pp. 31-48.
44. C. O'Driscoll, Novartis: White knight for Aventis? Chemistry & Industry, 16 February 2004, pp. 4 & 12.
45. K. S. Cleaves & A. M. Thayer, Warning, merge with care: Sanofi-Aventis, Modern Drug Discovery, August 2004, pp. 21-22.
46. EIRO Online, Employees concerned over Sanofi Synthelabo takeover bid for Aventis, European Industrial Relations Observatory On-Line, 2004, European Foundation for the Improvement of Living and Working Conditions.
47. Op. cit. ref. 15.
48. Cited in G. Dyer, Limited pipeline hampers senior partner, Financial Times, 27 January 2004.
49. Op. cit. ref. 38.
50. Op. cit. ref. 15;
51. op. cit. ref. 22.
52. Op. cit. ref. 38, p. 21.
53. C. Berggren, Mergers, MNES and innovation - the need for new research approaches, paper presented at the ESRC Transnational Communities Conference on Multinational Enterprises, Warwick, 6-8 September 2001.
54. Op. cit. Danzon et al. ref. 5.
55. S. Sudarsanam & A. Mahate, Are friendly acquisitions too bad for shareholders and managers? Longterm value creation and top management turnover in hostile and friendly acquirers, British Journal of Management, 17, 2006, pp. 7-30.
56. Cited in M. Arnold, Sanofi 'is in a hurry' to take over Aventis, Financial Times, 27 January 2004.
57. Cited in M. Arnold & H. Williamson, Aventis board dismisses hostile Sanofi bid, Financial Times, 28 January 2004.
58. Cited in G. Dyer, L. Saigol & B. Benoit, Anger grows over hostile Aventis bid, Financial Times, 27 January 2004.
59. Financial Times, 2 February 2004.
60. For a critical analysis of changing strategies in pharmaceutical advertising and corporate promotion, see J. Bower, From the 'rhetoric of hope' to the 'patient-active' paradigm: Strategic positioning of pharmaceutical and biotechnology companies, Technology Analysis and Strategic Management, 17(2), pp. 183-204.
61. Cited in G. Dyer & M. Arnold, Sanofi dismisses idea of a merger, Financial Times, 16 February 2004.
62. J. Cioffi, Governing globalization? The state, law, and structural change in corporate governance, Journal of Law and Society, 27(4), 2000, pp. 572-600;
63. See also L. Weiss, The Myth of the Powerless State, (Ithaca, NY, Cornell University Press, 1998)
64. and S. Berger & R.P. Dore (Eds), National Diversity and Global Capitalism (Ithaca, NY, Cornell University Press, 1996).
65. Op. cit. Cioffi ref. 54.
66. Ibid., p. 587.
67. P. Gallis, France: Factors Shaping Foreign Policy, and Issues in US-French Relations, CRS Report for Congress, Library of Congress, RL32464.
68. See K. Bennhold, Sarkozy urges Europe to forge industrial hubs, IHT, 5 May 2004, p. 1.
69. PharmaFocus.com, The wealth of evidence: The stories that changed pharma in 2004, 2 April 2006 (public statement given to journalists).
70. Reported by M. Arnold et al., Talks deepen between Novartis and Aventis, Financial Times, 18 March 2004.
71. Cited in M. Arnold, G. Dyer & H. Simonian, France vows to block bid by Novartis, Financial Times, 25 March 2004 (original statement given to French Newspaper, Le Figaro, a paper close to the French ruling centre-right UMP Party).
72. H. Simonian, Novartis qualifies Aventis interest, Financial Times, 23 March 2004.
73. See Wall Street Journal Europe, Aventis scrambles to find defense to takeover offer, 27 January 2004,
74. and International Herald Tribune, Bid to create French drug giant, 26 January 2004.
75. Cited in Financial Times, 21 April 2004.
76. R. Milne & H. Simonian, France gets its national champion, Financial Times, 25 April 2004.
77. Nature Biotechnology, Sanofi takeover jeopardizes Aventis biotech deals, Nature Biotechnology, 22(6), June 2004, pp. 639-640.
78. Ibid.
79. Ibid., p. 640.
80. Op. cit. ref. 13.
81. B. Groom, Can French big pharma look beautiful? Financial Times, 30 July 2004.
82. Op. cit. ref. 4.
83. Op. cit. Tait & Mittra ref. 31, p. 24.
84. I would like to thank my colleagues, Prof. Joyce Tait and Prof. David Wield for their constructive comments on early drafts of this article. I would also like to thank the anonymous reviewers for their advice on how to improve the paper. This article emerged from an ESRC funded project-Innovation Processes in Life Science Industries-within the ESRC Innogen Centre, University of Edinburgh.